Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Communiqués de presse de la société INNATE PHARMA
01/05Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Devel..
GL
01/05INNATE PHARMA : first NK cell engager selected by Sanofi as drug candidate for d..
GL
01/04Innate Pharma to Participate in Upcoming Investor Conferences
GL
01/04INNATE PHARMA : to participate in upcoming investor conferences
GL
2020INNATE PHARMA : to return US and EU Lumoxiti commercialization rights to AstraZe..
AQ
2020Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZ..
GL
2020INNATE PHARMA :  Innate Pharma to return US and EU Lumoxiti commercialization ri..
GL
2020Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combinat..
GL
2020INNATE PHARMA : to Present Additional Efficacy Data for Monalizumab in Combinati..
AQ
2020INNATE PHARMA :  Innate Pharma to present additional efficacy data for monalizum..
GL
2020INNATE PHARMA : 2021 financial calendar
GL
2020Innate Pharma 2021 Financial Calendar
GL
2020INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
2020INNATE PHARMA : Revenue for Q3
PU
2020INNATE PHARMA : reports third quarter 2020 financial results and business update
PU
2020INNATE PHARMA : Reports Third Quarter 2020 Financial Results and Business Update
AQ
2020INNATE PHARMA : reports third quarter 2020 financial results and business update
AQ
2020Innate Pharma Reports Third Quarter 2020 Financial Results and Business Updat..
GL
2020INNATE PHARMA : reports third quarter 2020 financial results and business update
GL
2020INNATE PHARMA : receives PRIME designation from the European Medicines Agency fo..
AQ
2020INNATE PHARMA : to participate in upcoming investor conferences
AQ
2020INNATE PHARMA : Receives Prime Designation From the European Medicines Agency fo..
AQ
2020INNATE PHARMA : Receives prime designation from the european medicines agency fo..
GL
2020INNATE PHARMA : Receives prime designation from the european medicines agency fo..
AQ
2020Innate Pharma Receives Prime Designation From the European Medicines Agency f..
GL
2020INNATE PHARMA : to Participate in upcoming investor conferences
AQ
2020INNATE PHARMA : to participate in upcoming investor conferences
AQ
2020INNATE PHARMA : to participate in upcoming investor conferences
GL
2020Innate Pharma to Participate in upcoming investor conferences
GL
2020INNATE PHARMA LAUNCHES HOPECONNECTLE : A New Online Resource for Hairy Cell Leuk..
AQ
2020INNATE PHARMA LAUNCHES HOPECONNECTLE : A New Online Resource for Hairy Cell Leuk..
GL
2020INNATE PHARMA : SA - First patient dosed in monalizumab Phase 3 clinical trial t..
AQ
2020INNATE PHARMA : First patient dosed in monalizumab Phase 3 clinical trial trigge..
AQ
2020ASTRAZENECA : First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers..
AQ
2020INNATE PHARMA : First patient dosed in monalizumab Phase 3 clinical trial trigge..
GL
2020First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payme..
GL
2020INNATE PHARMA : Interim financial report
PU
2020INNATE PHARMA : reports first half 2020 financial results and business update
AQ
2020INNATE PHARMA : Reports First Half 2020 Financial Results and Business Update
AQ
2020INNATE PHARMA : reports first half 2020 financial results and business update
GL
2020Innate Pharma Reports First Half 2020 Financial Results and Business Update
GL
2020Upcoming Investor Conferences
GL
2020INNATE PHARMA : obtains EUR6.8M in public funding for its COVID-19 research and ..
AQ
2020Innate Pharma Obtains €6.8M in Public Funding for Its COVID-19 Research And D..
GL
2020Innate Pharma Announces Publication of EXPLORE COVID-19 Translational Study F..
GL
2020INNATE PHARMA : announces the appointment of Joyson Karakunnel, MD, MSC, FACP as..
GL
2020INNATE PHARMA : U.S. Food and Drug Administration lifts partial clinical hold on..
GL
2020U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TE..
GL
2020Outcome Of Annual General Meeting Of May 19, 2020
GL
2020INNATE PHARMA : Written questions to the Annual General Meeting
PU
2020INNATE PHARMA : to Present New Efficacy Data For Monalizumab in Combination With..
GL
2020Innate Pharma to Present New Efficacy Data for Monalizumab in Combination Wit..
GL
2020INNATE PHARMA : Revenue for Q1
PU
2020INNATE PHARMA : First Quarter 2020 Report
GL
2020INNATE PHARMA : AGM convening Notice BALO
PU
2020INNATE PHARMA : Text of resolutions to the 2020 AGM
PU
2020INNATE PHARMA : Financial resolutions tables
PU
2020INNATE PHARMA : Auditor's report PCAOB
PU
2020INNATE PHARMA : Convening brochure to the 2020 AGM
PU
2020INNATE PHARMA : Executive board report to the 2020 AGM
PU
2020INNATE PHARMA : Governance report (Say on Pay extract)
PU
2020First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patien..
GL
2020Innate Pharma Files Its 2019 Universal Registration Document (Document d'enre..
GL
2020INNATE PHARMA : AGM rectified Notice of Meeting BALO
PU
2020INNATE PHARMA : to Hold Its Annual General Meeting of Shareholders on May 19, 20..
AQ
2020INNATE PHARMA : First patient dosed in IPH5201 Phase I clinical trial in advance..
AQ
2020First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumor..
GL
2020INNATE PHARMA : reports full year 2019 financial results and business update
GL
2020INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
2020INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
2020Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
2020INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
2020French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitme..
GL
2020INNATE PHARMA : French regulatory agency agrees lacutamab TELLOMAK trial can res..
GL
2020INNATE PHARMA : Provides update from regulatory agencies on lacutamab tellomak t..
GL
1  2  3  4  5  6  7Next
Upcoming event on INNATE PHARMA